Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis Check our all-new video abstract from Christopher G. Bunick MD PhD, who gives structural insights into what makes some…
Read More
Curated by the JDD Editors Missed any of our August highlights? August is our psoriasis issue–a must-read. Catch up with this curated roundup from the JDD Editors—your guide to must-read articles…
Read More
Check Out JDD Corner’s Latest Author Spotlight Our latest Author Spotlight shines on Mark G. Lebwohl, MD, co-author of “Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination…
Read More
A Concise Look at the IMMPulse Trial Comparing Apremilast And Risankizumab In Moderate Plaque Psoriasis In a compelling video interview for the Journal of Drugs in Dermatology, Dr. Christopher Bunick…
Read More
Boosting Psoriasis Outcomes with a Dual Strategy - Deucravacitinib Plus Calcipotriene/Betamethasone Foam Shows Lasting Benefits A promising new open-label study in our August issue highlights how adding topical calcipotriene/betamethasone dipropionate…
Read More
Can Probiotics Help Psoriasis? This Study Says Yes—And Here’s Why You Should Pay Attention Could your next psoriasis treatment plan include probiotics? A randomized, double-blind, placebo-controlled trial published in JDD’s June…
Read More
Explore JDDonline If you’re on the hunt for expert-led, handpicked resources on psoriasis, you’re in the right place. Whether you're brushing up on the latest treatment insights or looking for…
Read More
Did you miss this March article? Generalized pustular psoriasis (GPP) is a serious and unpredictable skin condition with limited treatment options. The Effisayil 1 trial evaluated spesolimab, a monoclonal antibody…
Read More
Featured Podcast What a time to be a psoriasis patient, decades into the golden age of management strategies. With an embarrassment of treatment riches, all patients are clear right? Slow…
Read More
JDD Spotlight: Guselkumab's 5-Year Promise in Psoriasis Curious about long-term breakthroughs in psoriasis care? A recent pooled analysis from the Phase 3 VOYAGE studies hints that guselkumab might be a…
Read More
PSO Exciting: Clinical Pearls and Emerging Therapies For Psoriasis The field of dermatology continues to evolve at a rapid pace, bringing groundbreaking research from the lab to the clinic. As…
Read More
Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis Check our all-new video abstract from Christopher G. Bunick MD PhD, who gives structural insights into what makes some…
Read More
